MicroRNA-133 mediates cardiac diseases: Mechanisms and clinical implications.
MicroRNAs (miRNAs) belong to the family of small non-coding RNAs that mediate gene expression by post-transcriptional regulation. Increasing evidence have demonstrated that miR-133 is enriched in muscle tissues and myogenic cells, and its aberrant expression could induce the occurrence and development of cardiac disorders, such as cardiac hypertrophy, heart failure, etc. In this review, we summarized the regulatory roles of miR-133 in cardiac disorders and the underlying mechanisms, which suggest that miR-133 may be a potential diagnostic and therapeutic tool for cardiac disorders.
Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang 524023, Guangdong, China.
Yi
Y
Liu
Guangdong Key Laboratory for Research and Development of Natural Drugs, Guangdong Medical University, Zhanjiang 524023, Guangdong, China.
Yan
Y
Liang
Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China.
Jin-Fang
JF
Zhang
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Electronic address: fuweiming76@smu.edu.cn.
Wei-Ming
WM
Fu
D000818:Animals; D005786:Gene Expression Regulation; D006331:Heart Diseases / Q000235:genetics*; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D008954:Models, Biological; D009154:Mutation / Q000235:genetics
D035683:MicroRNAs
Cardiac hypertrophy; Heart disease; MiR-133; MicroRNAs; Target genes